Bacillus Calmette-Guerin (BCG)

BIOLOGICAL5 trials

Sponsors

Memorial Sloan Kettering Cancer Center, The University of Texas Health Science Center at San Antonio, AstraZeneca, Massachusetts General Hospital, Ankara University

Conditions

Bladder CancerHealthyNon Muscle Invasive Bladder CancerNon-muscle-invasive Bladder Cancer

Early Phase 1

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

CompletedNCT02326168

The University of Texas Health Science Center at San AntonioBladder Cancer

Start: 2013-10-31End: 2015-10-31Updated: 2017-01-25

Phase 2

A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.

CompletedNCT04507126

Massachusetts General HospitalHealthy

Start: 2021-03-01End: 2022-12-09Updated: 2025-12-12

Phase 3

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

TerminatedNCT00974818

Memorial Sloan Kettering Cancer CenterBladder Cancer

Start: 2009-09-30End: 2012-03-31Updated: 2015-11-20

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Active, not recruitingNCT03528694

AstraZenecaNon-muscle-invasive Bladder Cancer

Start: 2018-05-14End: 2028-10-03Updated: 2025-11-25

Phase 4

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

CompletedNCT06767982

Ankara UniversityNon Muscle Invasive Bladder Cancer

Start: 2019-01-01End: 2022-12-31Updated: 2025-01-10

Related Papers

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

2025-10-174 citations

The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami?

2025-08-051 citations

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial

OncoImmunology2019-05-2536 citations

A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).

Journal of Clinical Oncology2019-03-0119 citations